Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Inclusion Criteria: * Age ≥ 2 and ≤ 11 years old. * Diagnosis of AD according to the American Academy of Dermatology Consensus (2014) Criteria. * With moderate-to-severe AD, and inadequate response to topical medications. Exclusion Criteria: * Prior treatment with Stapokibart * Treatment with dupilumab within 13 weeks prior to the baseline visit, or treatment with anti-IgE(Immunoglobulin E) monoclonal antibody，other biological agents within 5 half-lives prior to the baseline visit . * Treatment with immunosuppressants/immunomodulatory drugs, ultraviolet therapy, or systemic traditional Chinese medicine for AD within 4 weeks prior to the baseline visit. * Treatment with a topical corticosteroids (TCS), topical calcineurin inhibitor (TCI) or topical Phosphodiesterase-4(PDE-4) inhibitor within 1 weeks prior to the baseline visit. * History of atopic keratoconjunctivitis invading cornea. * Acute attacks of Atopic Dermatitis within 4 weeks prior to the baseline visit. * Planned major surgical procedure during the patient's participation in this study.